Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07296744Not ApplicableNot Yet Recruiting

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

Role: lead

NCT07407816Not ApplicableRecruiting

Feasibility Study of the Supira System in Patients Undergoing HRPCI With Support Beyond the PCI Procedure

Role: lead

NCT06565039Not ApplicableWithdrawn

A Safety and Effectiveness Study of the Supira System in Patients Undergoing HRPCI - CE Study

Role: lead

NCT06087575Not ApplicableCompleted

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

Role: lead

NCT05864248Not ApplicableActive Not Recruiting

Feasibility Study SA of the Supira System for HRPCI

Role: lead

All 5 trials loaded